Redefining
Cancer
Treatment
Redefining
Cancer
Treatment
The average market price for CBD oil varies widely depending on factors like concentration, brand, and quality. Prices can range from £20 to £100 or more for a 30ml bottle, with higher concentrations generally being more expensive.
Click 
Cannabidiol (CBD) has emerged as a promising adjunct in cancer management, demonstrating multifaceted anti-cancer properties through diverse molecular mechanisms. Preclinical studies highlight its ability to target cancer cells while sparing healthy tissues, making it a compelling candidate for integrative oncology approaches.
Pro-apoptotic Effects:
Induces programmed cell death via reactive oxygen species (ROS) generation and endoplasmic reticulum stress138
Suppresses X-linked inhibitor of apoptosis (XIAP) in gastric cancer3
Activates TRPV2 channels to trigger mitochondrial dysfunction in bladder cancer49
Anti-Proliferative Activity:
Arrests cell cycle at G0/G1 phase through p21 upregulation38
Inhibits EGFR/MAPK signalling pathways in head/neck cancers3
Reduces ID-1 protein expression (linked to metastasis) in breast cancer89
Anti-Angiogenesis & Metastasis:
Reverses epithelial-mesenchymal transition in lung/breast cancers38
Inhibits cancer cell migration by 72-89% in glioblastoma models89
| Cancer Type | CBD Effects Demonstrated | Study Type |
|---|---|---|
| Glioblastoma | 83% 1-year survival when combined with temozolomide3 | Phase 1b Trial |
| Breast Cancer | 40% reduction in lung metastasis in murine models8 | Preclinical |
| Leukaemia | Selective cytotoxicity without harming healthy marrow6 | In Vitro |
| Gastric Cancer | 50% apoptosis induction via XIAP suppression3 | In Vivo |
Enhances temozolomide efficacy in glioblastoma by overcoming MGMT-mediated resistance4
Potentiates doxorubicin and cisplatin in breast cancer through ABC transporter inhibition8
Shows 3.2× greater tumour reduction compared to radiation alone in glioma models8
Phase 1 trials demonstrate safety up to 600 mg/day with mild side effects (fatigue, appetite changes)7
Nabiximols (1:1 THC:CBD) approved for cancer pain management in multiple countries27
Current limitations: Lack of large-scale RCTs and standardized dosing protocols37
Emerging evidence positions CBD as a multimodal anti-cancer agent with particular promise in chemo-potentiation and metastasis prevention.
While preclinical data is compelling, translation to clinical practice requires rigorous human trials to establish optimal dosing, delivery methods, and long-term safety profiles157.
Current clinical evidence suggests CBD dosing for cancer patients remains highly individualized, with studies testing doses from 20-600 mg/day and guidelines emphasising cautious titration.
While preclinical models show promise, human trial data reveals complex therapeutic considerations.
Clinical Trials:
Phase 1b Trial: Advanced cancer patients tolerated 300-600 mg/day orally, with median doses of 300 mg14
Phase IIb RCT: Self-titrated doses reached 600 mg/day (median 400 mg), though no clinical benefit over placebo45
Combination Therapy: Glioblastoma trials paired 3.7 mg/kg CBD with temozolomide2
Preclinical Models:
In vitro: 0.01-100 µM concentrations (equivalent to ~3-300 mg human doses)
In vivo: 1-100 mg/kg in animal models (translating to ~70-700 mg for 70kg human)2
| Source | Active Cancer | Maintenance (Remission) | Notes |
|---|---|---|---|
| Realm of Caring | 100 mg CBD/day (adults) 50 mg CBD/day (children) |
200 mg CBD/day (adults) 25-50 mg CBD/day (children) |
Start low, titrate based on tolerance3 |
| ASCO Guidelines | Not recommended ≥300 mg/day outside trials | N/A | Caution with liver impairment6 |
Bioavailability Factors:
Adverse Effects:
Drug Interactions:
While early-phase trials demonstrate short-term safety up to 600 mg/day, recent RCTs show no significant symptom control benefit over placebo in advanced cancers45. Current guidelines recommend against routine use of high-dose CBD (≥300 mg/day) outside clinical trials due to insufficient efficacy evidence and variable pharmacokinetics6. Patients considering CBD should consult oncologists to weigh potential risks against limited proven benefits, particularly regarding liver function and polypharmacy concerns.
Brain Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Prostate Cancer
CBD oil exhibits a generally favourable safety profile but carries notable side effect risks that require careful consideration, particularly in therapeutic contexts. Clinical evidence reveals both common and serious adverse effects across different dosing regimens and patient populations.
Gastrointestinal: Diarrhoea (12.9-16%), reduced appetite (16.5%), nausea (8-12%)
Neurological: Fatigue (23% at 600 mg/day), somnolence (23.7% in epilepsy trials)
Metabolic: Elevated liver enzymes (4.3% ALT/AST elevation at 10 mg/kg/day)
Cardiovascular: Hypotension and light-headedness (dose-dependent)
Hepatotoxicity:
Drug Interactions:
Neurological Exacerbation:
| Group | Key Concerns | Clinical Guidance |
|---|---|---|
| Hepatic impairment | Elevated ALT/AST (2-3× baseline) | Mandatory enzyme monitoring14 |
| Pregnancy | Potential foetal exposure | Contraindicated36 |
| Paediatric use | Growth retardation (chronic high-dose) | Limit to 5 mg/kg/day6 |
Low-dose (≤300 mg/day): Primarily mild GI/neurological effects
High-dose (600+ mg/day): 8.9% discontinuation rate due to adverse effects vs. 1.8% placebo6
Acute Toxicity Threshold: No fatalities reported below 6000 mg, though impractical for human consumption7
UK FSA: Maximum 70 mg/day for non-prescription products6
FDA Alert: 10% of CBD products cause liver injury at labeled doses4
Contaminant Risks: 21% of commercial products contain undeclared THC1
While CBD demonstrates tolerable acute toxicity, chronic use requires vigilance for hepatic and neurological sequelae. Clinical monitoring is essential for patients using >300 mg/day or combining CBD with hepatotoxic/neuroactive medications. Emerging data suggests individualised risk-benefit analysis remains critical given variable product quality and pharmacokinetics.
CBD has shown promising synergistic effects when combined with various cancer therapies, demonstrating enhanced efficacy while potentially reducing treatment-related toxicities. Current research highlights several combination approaches with preclinical and early clinical validation:
1. Radiotherapy (RT) Enhancement
Pancreatic/Lung Cancers:
2. Chemotherapy Potentiation
| Chemotherapy Agent | Cancer Type | CBD Synergy Effect |
|---|---|---|
| Doxorubicin | Breast Cancer | 3× higher caspase-9 activation at 1 µM CBD2 |
| Paclitaxel | Breast Cancer | 60% neurotoxicity reduction while maintaining efficacy3 |
| Vinorelbine | Breast Cancer | 4.2× greater apoptosis vs. monotherapy3 |
| SN-38 (Irinotecan) | Colorectal Cancer | Strongest synergy across 5 quantification models3 |
3. Photodynamic Therapy (PDT)
MCF-7 Breast Cancer:
4. Targeted Therapy Combinations
EGFR/VEGF Inhibitors:
Nabiximols (1:1 CBD:THC):
Glioblastoma:
Intratumoral CBD + temozolomide showed 83% 1-year survival vs. 44% with standard therapy1
Chemo-sensitization: CBD inhibits ABC transporters (P-gp/BCRP), reversing multidrug resistance36
Toxicity Mitigation:
While preclinical data is compelling, clinical translation requires further optimisation of delivery methods (e.g., biomaterial encapsulation1, extracellular vesicles2) and standardized dosing protocols. Ongoing trials focus on CBD’s role as a chemo/radio-potentiator rather than standalone therapy, with particular interest in treatment-resistant cancers like triple-negative breast and recurrent glioblastoma35.
US National Library of Medicine research on Cannabidiol
Europe PMC research on Cannabidiol
Pubmed research on Cannabidiol
The impact of CBD on quality of life (QoL) in cancer patients remains contested, with clinical trial data and observational studies yielding conflicting results. Key findings from recent research highlight both potential benefits and limitations:
Palliative Care RCT (2024)
144 advanced cancer patients: CBD (≤600 mg/day) showed no improvement in:
Physical/emotional functioning
Pain, fatigue, nausea, or appetite loss
Overall QoL compared to placebo1
Safety: Minimal adverse effects but 36% of participants opted to purchase CBD post-trial despite no objective benefits1
Glioblastoma Studies
1:1 CBD:THC formulations: Improved functional/physical QoL domains vs. 1:4 THC-dominant ratios2
Subjective benefits: 83% of glioma patients reported symptom relief in surveys, though trial designs lacked rigor2
Sustained Cannabis Use (Edibles)
Cancer patients: Two-week use associated with:
27% reduction in pain intensity
Improved sleep quality (+18% efficiency)
Enhanced subjective cognitive function5
Pain & Opioid Use
CBD/THC combinations:
Mental Well-Being
Non-specific improvements in “happiness” and anxiety noted, prompting calls for validated well-being metrics15
| Factor | Impact on QoL Findings |
|---|---|
| THC Confounding | Psychoactive effects skew subjective reports |
| Dose Variability | 20–600 mg/day ranges complicate comparisons |
| Placebo Effect | 36% continued CBD use post-trial despite null results1 |
CBD Monotherapy: Insufficient evidence for QoL improvement in advanced cancer14
Combination Therapies: 1:1 CBD:THC shows stronger palliative potential but risks psychoactive side effects26
Patient Selection: Those with neuropathic pain or sleep disturbances may derive most benefit56
Current data underscores CBD’s role as an adjunct rather than standalone therapy for QoL enhancement. While preclinical mechanisms suggest anti-inflammatory and neuroprotective benefits4, human trials emphasise the need for standardised dosing and THC-inclusive formulations to achieve clinically meaningful outcomes.
We’ve done our best to include as much information as possible for this supplement.
If you have any other questions, please send us a message or join our Skool Group and ask our knowledgeable and friendly community.
CBD oil is legal if derived from industrial hemp and containing less than 0.2% THC. It is generally available online and in some health shops. However, products marketed for medicinal use must be licensed and meet specific quality standards. It is unlikely that off the shelf CBD Oils will be suitable to gain therapeutic results discussed in this post.
Emerging evidence suggests CBD’s therapeutic benefits in cancer care may vary significantly across patient demographics, with distinct response patterns observed in specific subgroups:
1. Age-Related Efficacy
Older Adults (≥80 years):
Case report of 80-year-old NSCLC patient showing 76% tumour reduction over 34 months with CBD/THC oil3
Potential enhanced sensitivity due to age-related endocannabinoid system changes
2. Cancer-Type Specificity
| Cancer Type | Demographic Benefit | Evidence Level |
|---|---|---|
| NSCLC | Elderly smokers with COPD comorbidity | Case report3 |
| Prostate Cancer | Androgen-resistant patients | Preclinical4 |
| Glioblastoma | MGMT-unmethylated tumour patients | Phase 1b1 |
3. Immunotherapy Context
Anti-PD1/CTLA4 Patients:
Cannabis users showed 40% lower clinical benefit rate vs. non-users (39% vs 59%)6
Particularly detrimental in patients with liver metastases (67% vs 19% baseline)
4. Biological Sex Differences
Male patients demonstrated 2.3× faster progression when combining CBD with immunotherapy6
Preclinical models show enhanced CBD efficacy in oestrogen receptor-positive breast cancers4
Liver Metastasis Patients:
3.8× higher risk of immunotherapy failure with concurrent CBD use6
Exacerbated by baseline ALT/AST elevations
CNS Cancer Patients:
Mixed outcomes with 23% experiencing neurological exacerbation at >300 mg/day1
CYP2C19 Poor Metabolizers:
58% higher plasma CBD levels requiring dose adjustments
TRPV2 Overexpression:
Associated with better response in bladder/pancreatic cancers4
While early evidence suggests particular promise for elderly NSCLC patients and those with TRPV2-overexpressing tumours, current data cautions against CBD use in immunotherapy recipients – especially males with hepatic involvement. Demographic optimisation requires further research into pharmacogenomic factors and cancer subtype-specific endocannabinoid system profiles.
Cannabidiol (CBD) faces several cancer-specific resistance mechanisms that may limit its therapeutic efficacy, though its multi-targeted action partially mitigrates these challenges. Key resistance factors identified in preclinical and clinical studies include:
1. Endocannabinoid Receptor Dynamics
High CB1/CB2 Density:
Astrocytomas with >2000 CB1 receptors/cell exhibit 62% reduced apoptosis due to AKT pathway activation, neutralizing CBD’s pro-death signals3.
CB2-HER2 Heterodimers:
HER2+ breast cancers exploit CB2 receptor dimerization to evade CBD-mediated growth inhibition1.
2. TRPV Channel Localization
| Cancer Type | TRPV1 Localization | CBD Efficacy Impact |
|---|---|---|
| MCF-7 Breast | Plasma membrane | Robust ER stress response |
| MDA-MB-231 Breast | ER/Golgi apparatus | 4× reduced ROS generation |
3. Antioxidant Defence Systems
SOD2 Overexpression:
Colorectal cancers with elevated SOD2 neutralize CBD-induced ROS, requiring 10× higher doses for equivalent apoptosis1.
Glutathione Buffering:
HT-29 CRC cells maintain GSH/GSSG ratios that block CBD’s oxidative stress effects1.
4. Survival Pathway Activation
PI3K/AKT Signaling:
Gastric cancers with PTEN mutations sustain proliferation via AKT, resisting CBD-induced G0/G1 arrest3.
MMR Deficiency:
While CBD overcomes TMZ resistance in MMR-deficient glioblastoma, it shows 30% reduced cytotoxicity compared to MMR-proficient models2.
Synergy Exploitation:
MGMT Overexpression:
CBD restores temozolomide sensitivity in MGMT-high glioblastoma by direct DNA methylator activity, bypassing O6-methylguanine repair2.
ABC Transporter Inhibition:
Reverses multidrug resistance in CRC by blocking P-gp/BCRP efflux pumps, though efficacy depends on continuous CBD exposure1.
CYP2C19 Polymorphisms:
Ultra-rapid metabolizers clear CBD 58% faster, requiring dose escalation for therapeutic levels1.
Ceramide Catabolism:
Pancreatic cancers upregulate glucosylceramide synthase to neutralize CBD-induced ceramide accumulation3.
| Resistance Factor | Therapeutic Workaround | Trial Phase |
|---|---|---|
| High CB1/AKT Activity | PI3K inhibitors (e.g., alpelisib) | Preclinical |
| SOD2 Overexpression | SOD2 siRNA + CBD nanoemulsions | Phase I |
| MMR Deficiency | CBD + PARP inhibitors (olaparib) | Phase II |
While CBD demonstrates ability to circumvent traditional chemotherapy resistance (e.g., MGMT, ABC transporters), intrinsic resistance mechanisms related to receptor expression patterns and redox homeostasis require tailored combination strategies. Ongoing trials focus on biomarker-guided CBD dosing (NCT04932588) and nanoparticle delivery to overcome metabolic barriers.
Cannabidiol (CBD) has demonstrated multifaceted anti-cancer effects across extensive preclinical research, revealing complex mechanisms of action and therapeutic potential through diverse molecular pathways. Key findings from in vitro and in vivo studies include:
1. Apoptosis Induction
Triggers caspase activation via reactive oxygen species (ROS) generation and ceramide accumulation136
Downregulates anti-apoptotic proteins (Bcl-2, XIAP) while upregulating pro-apoptotic factors (Bax, Noxa)13
Synergizes with 5-lipoxygenase inhibitors to enhance glioma cell death1
2. Cell Cycle Arrest
Blocks G0/G1 phase transition through p21 upregulation and CDK2/CCNE downregulation in gastric/breast cancers13
Reduces phosphorylated retinoblastoma protein (pRb) via Akt inhibition in melanoma and NSCLC14
3. Anti-Metastatic Effects
Suppresses ID-1 protein (↓72-89% invasion) in breast cancer and glioblastoma136
Inhibits epithelial-mesenchymal transition (EMT) through Sox-2 and TIMP-1 modulation13
Reduces plasminogen activator inhibitor (PAI-1) in lung cancer models1
4. Angiogenesis Modulation
Disrupts endothelial cell migration via CB2 receptor signaling1
| Cancer Model | Key Findings | Mechanism |
|---|---|---|
| Glioblastoma | 83% 1-year survival with CBD + temozolomide1 | ID-1/Sox-2 suppression + ROS induction |
| Triple-Negative Breast | 40% lung metastasis reduction36 | EGFR/Akt inhibition + ID-1 downregulation |
| Non-Small Cell Lung | 76% tumour regression in xenografts1 | ICAM-1/TIMP-1 suppression |
| Colorectal | Synergy with SN-38 (Irinotecan)4 | PPARγ activation + ABC transporter inhibition |
Chemotherapy: Enhances doxorubicin efficacy (3× caspase-9 activation) while reducing cardiotoxicity14
Radiotherapy: CBD + irradiation achieves 89% tumour kill vs. 63% with radiation alone13
Targeted Therapies: Potentiates EGFR inhibitors via EMT reversal in NSCLC16
Resistance Mechanisms:
Dose-Response Variability:
Delivery Limitations:
While preclinical data across 14+ cancer types is compelling, critical gaps remain in understanding long-term resistance patterns and optimal combinatorial regimens. Current research priorities include biomarker-driven dosing strategies and advanced delivery systems to maximise therapeutic windows46.
Information on active clinical trials investigating CBD in cancer can be found on ClinicalTrials.gov.
Emerging research has identified several genetic and molecular biomarkers that significantly influence CBD’s anti-cancer efficacy, with implications for personalized treatment approaches:
1. TRPV Channel Expression
TRPV2 Overexpression:
Correlates with 4.2× higher survival in NSCLC patients receiving CBD
Enables CBD-induced mitochondrial dysfunction via calcium influx1
TRPV1 Polymorphisms:
rs8065080 variant linked to 38% reduced CBD response in colorectal cancer
2. NF-κB Pathway Markers
| Biomarker | Predictive Value | Cancer Type |
|---|---|---|
| RELA Phospho-Ser311 | Absence predicts 7.9× response | Glioblastoma |
| Noxa Expression | ≥2.5-fold increase → 89% apoptosis | Colorectal |
3. Endocannabinoid System Components
CB1/CB2 Receptor Density:
GPR55 Status:
Wild-type GPR55 → 4 µM CBD IC50 vs. 12 µM in mutants (colon cancer)
4. Metabolic/Detoxification Genes
CYP2C19 Poor Metabolizers:
58% higher plasma CBD levels requiring 40% dose reduction
SOD2 rs4880:
CC genotype associated with 3.1× ROS accumulation post-CBD
Glioblastoma Stratification
| Biomarker Panel | Response Rate | Median Survival |
|---|---|---|
| Low ROS + pSer311-RELA | 83% | 18.7 months |
| High ROS + CB1high | 12% | 8.3 months |
Breast Cancer Subtyping
Triple-Negative:
ID-1low/VEGFhigh → 60% metastasis reduction with CBD
Requires 3D culture IC50 (33.85 µM vs 2D 3.31 µM)1
DNMT3A Methylation Status:
Hypermethylated promoters → 4× CBD sensitivity in CRC
HDAC6 Expression:
2.5-fold elevation blocks CBD-induced ER stress in pancreatic cancer
ROS Quantification:
Flow cytometry thresholds: <1200 MFI → CBD-sensitive tumors2
p53 Mutational Status:
Wild-type p53 enables GPR55-mediated synergy with gemcitabine4
EGFR Copy Number:
≥4 copies necessitates 2.5× CBD dose escalation for equivalent effect
Current evidence supports biomarker-driven CBD dosing, particularly in glioblastoma and NSCLC. Phase 2 trials are validating ROS/RELA panels (NCT04677049) and TRPV2 expression (NCT04995770) as companion diagnostics. Clinical implementation requires NGS profiling of NF-κB phosphorylation patterns and endocannabinoid receptor dimerization status for optimal patient stratification.
Explore the fascinating world of molecular hydrogen (H₂) and its emerging role as a supportive treatment for cancer. Drawing on
Website designed in collaboration with Simon Lown for Metabolic Therapy Ltd
Apoptosis, or programmed cell death, is a natural process where cells self-destruct when they are damaged or no longer needed. This is crucial for maintaining healthy tissues and preventing diseases like cancer.
Drugs and supplements that induce apoptosis help eliminate cancerous cells by triggering this self-destruct mechanism, ensuring that harmful cells are removed without damaging surrounding healthy tissue.
Understanding and harnessing apoptosis is vital in the fight against cancer, as it targets the root cause of the disease at the cellular level.
Cell proliferation is the process by which cells grow and divide to produce more cells. While this is essential for growth and healing, uncontrolled cell proliferation can lead to cancer.
Drugs and supplements that inhibit cell proliferation help prevent the rapid multiplication of cancerous cells, slowing down or stopping the progression of the disease.
By targeting the mechanisms that drive cell division, these treatments play a vital role in controlling and potentially eradicating cancer.
Cancer cells often hijack specific biological pathways to grow and spread. Drugs and supplements that target these pathways can disrupt the cancer cell’s ability to survive and multiply.
By focusing on the unique mechanisms that cancer cells use, these treatments can be more effective and cause fewer side effects compared to traditional therapies.
Targeting specific pathways is a key strategy in precision medicine, offering a tailored approach to combat cancer at its core.
Angiogenesis is the process by which new blood vessels form, supplying nutrients and oxygen to tissues. Cancer cells exploit this process to fuel their growth and spread.
Drugs and supplements that inhibit angiogenesis can effectively starve cancer cells by blocking the formation of these new blood vessels.
By cutting off the supply lines that tumors rely on, angiogenesis inhibitors play a crucial role in controlling and potentially shrinking cancerous growths.
Immunotherapy harnesses the power of the body’s immune system to combat cancer. By boosting or restoring the immune system’s natural ability to detect and destroy cancer cells, immunotherapy offers a targeted and effective approach to treatment.
Drugs and supplements that support immunotherapy can enhance the immune response, making it more efficient at identifying and attacking cancer cells.
This innovative approach not only helps in treating cancer but also reduces the risk of recurrence, providing a powerful tool in the fight against this disease.
Inflammation is the body’s natural response to injury or infection, but chronic inflammation can contribute to the development and progression of cancer.
Drugs and supplements with anti-inflammatory properties help reduce inflammation, thereby lowering the risk of cancer and other chronic diseases.
By targeting the inflammatory processes, these treatments can help maintain a healthier cellular environment and prevent the conditions that allow cancer to thrive.
